MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its pipeline focuses on obesity and related conditions using its proprietary PEP platform.
UpMarket does not offer MBX Biosciences shares. This page covers MBX Biosciences's history before it went public.
MBX Biosciences became a public company on September 12, 2024 and trades on Nasdaq as MBX. UpMarket does not offer MBX Biosciences shares. This page covers MBX Biosciences's valuation and funding history before it went public.
MBX Biosciences listed on Nasdaq under the ticker MBX on September 12, 2024.
See how MBX Biosciences's private-market valuation changed across funding rounds before it went public.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Sep 2024 | IPO |
MBX said one-year follow-up data from its Phase 2 once-weekly canvuparatide study is expected in Q2 2026, with Phase 3 initiation targeted for Q3 2026. The company also expects Phase 1 12-week data for once-monthly MBX 4291 in Q4 2026, giving investors multiple clinical readouts this year.
MBX says its proprietary PEP platform is enabled by clinically validated Precision Endocrine Peptide technology and underpins its pipeline. The company’s pipeline includes MBX 4291, the lead amycretin prodrug MBX 5765, and a GLP-1/GIP/GCGR prodrug candidate, supporting a multi-asset strategy.
MBX says its growing pipeline is designed to create breakthrough change within underserved markets for endocrine and metabolic disorders. The company’s mission is to develop transformative medicines that are efficacious, safe, and accessible for these large disease areas.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. MBX Biosciences became a public company on September 12, 2024 and trades on Nasdaq under the ticker MBX. UpMarket does not offer MBX Biosciences shares.
MBX Biosciences's share price is set on the public market under the ticker MBX. The prices shown on this page are historical private-market prices from before it went public.
No. MBX Biosciences is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
MBX Biosciences is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review MBX Biosciences's public filings and consult a financial advisor before investing. UpMarket does not offer MBX Biosciences shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
MBX Biosciences became a public company on September 12, 2024, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer MBX Biosciences shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
MBX Biosciences's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, with $7.6M in 2023 revenue and a targeted Phase 3 canvuparatide start in Q3 2026. MBX Biosciences is now a public company, and UpMarket does not offer its shares.